Effluvium; Telogen Clinical Trial
Official title:
Demonstration of the Presence of Carbonyl Stress in the Hair Follicles of Women With Reactive Hair Loss
| Verified date | January 2018 |
| Source | Pierre Fabre Dermo Cosmetique |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
In this study, the investigator will try to highlight the presence of carbonyl compounds in the hair follicles of women with telogen effluvium (ET) linked to stress of various origins (fatigue, infectious diseases, emotional stress ...).
| Status | Completed |
| Enrollment | 40 |
| Est. completion date | June 25, 2018 |
| Est. primary completion date | June 25, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Female |
| Age group | 18 Years to 40 Years |
| Eligibility |
Inclusion Criteria: Criteria related to the Population : - Women aged from 18 to 40 ans (included) - Phototype I à IV included, according to Fitzpatrick Classification - Hair length 5 cm on the sampling area (centro-parietal part) - Last shampoo at least 2 days before the inclusion visit, without application of styling product, care or water between this last shampoo and the inclusion - Informed consent signature Criteria related to the studied condition: - ET group: hair loss related to various etiologies evaluated by a questionnaire according to the investigator's opinion and positive pull test (at least 3 hair collected per lock of 50 to 60 hair) AND - Control group : no hair loss, evaluated by the questionnaire and negative pull test (less than 3 hair collected per lock of 50 to 60 hair) Exclusion Criteria: Criteria related to Population : - Menopause - Pregnancy, breastfeeding, childbirth for less than 6 months Criteria related to Pathology : For both groups: - Alopecia causing hair loss on the upper part of the scalp - Dermatological pathology or evolving cutaneous lesion in the scalp - Control group only: - Chronic unstabilized condition - Acute evolving pathology Criteria related to theTreatments : For both groups: - Use for at least 1 month of Minoxidil, Aminexil in the 3 months before inclusion or ongoing - Systemic treatment affecting hair growth - Any treatment or dietary supplement for antioxidant or capillary Control group only: - Treatment of general thyroid disorders initiated or modified for less than 3 months prior to inclusion - Treatment of anemia if started less than 3 months before inclusion - General treatment initiated or modified for less than 3 months prior to inclusion in the study |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre hospitalier Lyon Sud | Lyon | |
| France | Centre de Pharmacologie Clinique Appliquée à la Dermatologie | Nice | |
| France | Centre de santé SABOURAUD | Paris | |
| France | INTERTEK France | Paris | |
| France | Centre de Recherche sur la Peau | Toulouse | |
| France | Laboratoire Dermscan | Villeurbanne |
| Lead Sponsor | Collaborator |
|---|---|
| Pierre Fabre Dermo Cosmetique |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Biological evaluation | Evaluation of the quantity of carbonyl compounds measured in the hair follicles taken from the two groups. | Visit 1- Day 1 | |
| Secondary | Safety evaluation | Adverse events evaluation | Visit 1- Day 1 |